Vol. 36 Suppl. 1 2008
■ Clinical Evaluation of Intravenous
Nicorandil（Sigmart®） in Patients with Acute Heart Failure
Safety, tolerability and pharmacokinetics
of bolus injection of high dose nicorandil（Sigmart® ）in
healthy subjects
─Phase I study─
J. Azuma, et al.
Jpn Pharmacol Ther 2008 36(s1) s5-14
Safety, tolerability and pharmacokinetics
of bolus injection followed by continuous infusion of nicorandil（Sigmart®）in
healthy subjects
─Phase I study─
J. Azuma, et al.
Jpn Pharmacol Ther 2008 36(s1) s15-24
Acute effects of a bolus intravenous
administration of nicorandil（Sigmart®）in patients with
acute heart failure or acute exacerbation of chronic heart failure
K. Kato, et al.
Jpn Pharmacol Ther 2008 36(s1) s25-34
Clinical evaluation of intravenous
nicorandil（Sigmart® ）infusion in patients with acute heart
failure or acute exacerbation of chronic heart failure
─Early phase II
study with bolus injection and continuous infusion─
K. Kato, et al.
Jpn Pharmacol Ther 2008 36(s1) s35-48
Dose finding study of intravenous
nicorandil（Sigmart®）in patients with acute heart failure
─The
multi-center, randomized double blind late phase II study─
K. Kato, et al.
Jpn Pharmacol Ther 2008 36(s1) s49-63
Clinical evaluation of intravenous
nicorandil（Sigmart® ）in patients with acute heart failure
─The
multi-center, randomized double blind placebo-controlled phase III study─
K. Kato, et al.
Jpn Pharmacol Ther 2008 36(s1) s65-78
Clinical evaluation of 48-hour intravenous
infusion of nicorandil（Sigmart® ）in patients with acute
heart failure
K. Kato, et al.
Jpn Pharmacol Ther 2008 36(s1) s79-90
